Schuette A, Lander DP, Kallogjeri D, et al. - For individuals with head and neck cancer, researchers created a prediction model for postradiotherapy and/or post–cisplatin chemotherapy hearing loss. According to findings, first accurate predictive model was created that agreed with 77% of the variability in the posttreatment 1-, 2-, and 4-kHz pure tone average in this cohort study of 242 individuals (482 ears). For anticipating an observed posttreatment pure tone average greater than 35 dB, this predictive model also had a sensitivity of 80% and specificity of 75%. Predictive models can provide cancer patients with accurate estimates of the changes occurring after irradiation and cisplatin chemotherapy in their hearing. This study indicates that in patients with head and neck cancer, cochlea exposure to cisplatin chemotherapy and radiotherapy is related to hearing loss.